NASDAQ:SRNE - Sorrento Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.80 +0.20 (+3.03 %)
(As of 07/20/2018 05:01 AM ET)
Previous Close$6.60
Today's Range$6.56 - $6.85
52-Week Range$1.50 - $10.65
Volume1.10 million shs
Average Volume2.91 million shs
Market Capitalization$785.37 million
P/E RatioN/A
Dividend YieldN/A
Beta2.47
Sorrento Therapeutics logoSorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company is focusing on the development of chimeric antigen receptor (CAR)-based immunotherapies using autologous T-cells. It is developing CD38 Directed CAR-T, a cellular therapy used for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; CD123 Directed CAR-T for the treatment of acute myelogenous leukemia; and human antibodies, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT, and CD137. The company is also developing intracellular targeting antibodies comprising STAT3, Mutant KRAS, MYC, p53, and TAU to modulate the evolution of cancer, inflammation, autoimmune diseases, diabetes, central nervous system diseases, cardiovascular diseases, and viral infections; and oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. In addition, it offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company has a licensing agreement with Mabtech Limited to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from based on Erbitux, Remicade, Xolair, and Simulect. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

Receive SRNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SRNE
CUSIPN/A
Phone858-203-4100

Debt

Debt-to-Equity Ratio0.02
Current Ratio0.71
Quick Ratio0.71

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$151.85 million
Price / Sales5.17
Cash Flow$0.2255 per share
Price / Cash30.15
Book Value$2.50 per share
Price / Book2.72

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$9.13 million
Net Margins23.25%
Return on Equity21.91%
Return on Assets8.31%

Miscellaneous

Employees162
Outstanding Shares115,500,000
Market Cap$785.37

Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics Inc (NASDAQ:SRNE) released its earnings results on Monday, November, 16th. The biopharmaceutical company reported ($0.03) EPS for the quarter. The biopharmaceutical company earned $1.10 million during the quarter, compared to analyst estimates of $1.28 million. Sorrento Therapeutics had a return on equity of 21.91% and a net margin of 23.25%. View Sorrento Therapeutics' Earnings History.

What price target have analysts set for SRNE?

5 brokerages have issued twelve-month price targets for Sorrento Therapeutics' shares. Their predictions range from $7.00 to $40.00. On average, they anticipate Sorrento Therapeutics' stock price to reach $15.45 in the next year. This suggests a possible upside of 127.2% from the stock's current price. View Analyst Ratings for Sorrento Therapeutics.

What is the consensus analysts' recommendation for Sorrento Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting Sorrento Therapeutics?

Sorrento Therapeutics saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 19,659,939 shares, an increase of 21.9% from the June 15th total of 16,123,092 shares. Based on an average daily volume of 3,653,853 shares, the short-interest ratio is currently 5.4 days. Currently, 22.5% of the shares of the company are sold short. View Sorrento Therapeutics' Current Options Chain.

Who are some of Sorrento Therapeutics' key competitors?

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the folowing people:
  • Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 54)
  • Mr. George K. Ng, Exec. VP, Chief Admin. Officer & Chief Legal Officer (Age 44)
  • Dr. Jerome Bernard Zeldis, Chief Medical Officer and Pres of Clinical Research, Medical Affairs & Regulatory (Age 68)
  • Mr. Jiong Shao CFA, Exec. VP & CFO (Age 50)
  • Dr. Alexis Nahama, VP of Corp. Devel.

Has Sorrento Therapeutics been receiving favorable news coverage?

Media headlines about SRNE stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sorrento Therapeutics earned a coverage optimism score of 0.06 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.79 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $6.80.

How big of a company is Sorrento Therapeutics?

Sorrento Therapeutics has a market capitalization of $785.37 million and generates $151.85 million in revenue each year. Sorrento Therapeutics employs 162 workers across the globe.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]


MarketBeat Community Rating for Sorrento Therapeutics (NASDAQ SRNE)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  354 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  499
MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe SRNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.